Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death A Arlt, A Gehrz, S Müerköster, J Vorndamm, ML Kruse, UR Fölsch, ... Oncogene 22 (21), 3243-3251, 2003 | 609 | 2003 |
Interaction of tumor cells with the microenvironment H Ungefroren, S Sebens, D Seidl, H Lehnert, R Hass Cell Communication and Signaling 9, 1-8, 2011 | 410 | 2011 |
Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene … A Arlt, S Sebens, S Krebs, C Geismann, M Grossmann, ML Kruse, ... Oncogene 32 (40), 4825-4835, 2013 | 348 | 2013 |
Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2) A Arlt, I Bauer, C Schafmayer, J Tepel, SS Müerköster, M Brosch, C Röder, ... Oncogene 28 (45), 3983-3996, 2009 | 334 | 2009 |
The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects K Hattermann, J Held-Feindt, R Lucius, SS Müerköster, MET Penfold, ... Cancer research 70 (8), 3299-3308, 2010 | 308 | 2010 |
Tumor‐associated macrophages exhibit pro‐and anti‐inflammatory properties by which they impact on pancreatic tumorigenesis O Helm, J Held‐Feindt, E Grage‐Griebenow, N Reiling, H Ungefroren, ... International journal of cancer 135 (4), 843-861, 2014 | 289 | 2014 |
Targeting apoptosis pathways in pancreatic cancer A Arlt, SS Müerköster, H Schäfer Cancer letters 332 (2), 346-358, 2013 | 177 | 2013 |
CX3CR1 promotes recruitment of human glioma-infiltrating microglia/macrophages (GIMs) J Held-Feindt, K Hattermann, SS Müerköster, H Wedderkopp, ... Experimental cell research 316 (9), 1553-1566, 2010 | 165 | 2010 |
Novel bispecific antibodies increase γδ T-cell cytotoxicity against pancreatic cancer cells HH Oberg, M Peipp, C Kellner, S Sebens, S Krause, D Petrick, ... Cancer research 74 (5), 1349-1360, 2014 | 154 | 2014 |
Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells S Sebens Müerköster, V Werbing, B Sipos, MA Debus, M Witt, ... Oncogene 26 (19), 2759-2768, 2007 | 148 | 2007 |
Differential roles of Smad2 and Smad3 in the regulation of TGF-β1-mediated growth inhibition and cell migration in pancreatic ductal adenocarcinoma cells: control by Rac1 H Ungefroren, S Groth, S Sebens, H Lehnert, F Gieseler, F Fändrich Molecular cancer 10, 1-16, 2011 | 137 | 2011 |
Cytoprotection “gone astray”: Nrf2 and its role in cancer C Geismann, A Arlt, S Sebens, H Schäfer OncoTargets and therapy, 1497-1518, 2014 | 129 | 2014 |
Usage of the NF‐κB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer S Müerköster, A Arlt, M Witt, A Gehrz, S Haye, C March, F Grohmann, ... International journal of cancer 104 (4), 469-476, 2003 | 128 | 2003 |
Diabetes as risk factor for pancreatic cancer: Hyperglycemia promotes epithelial-mesenchymal-transition and stem cell properties in pancreatic ductal epithelial cells S Rahn, V Zimmermann, F Viol, H Knaack, K Stemmer, L Peters, L Lenk, ... Cancer letters 415, 129-150, 2018 | 126 | 2018 |
CD95 and TRAF2 promote invasiveness of pancreatic cancer cells A Trauzold, C Röder, B Sipos, K Karsten, A Arlt, P Jiang, JI Martin-Subero, ... The FASEB journal 19 (6), 1-24, 2005 | 122 | 2005 |
EMT-associated up-regulation of L1CAM provides insights into L1CAM-mediated integrin signalling and NF-κB activation H Kiefel, S Bondong, M Pfeifer, U Schirmer, N Erbe-Hoffmann, H Schäfer, ... Carcinogenesis 33 (10), 1919-1929, 2012 | 97 | 2012 |
The tumor stroma as mediator of drug resistance-a potential target to improve cancer therapy? S Sebens, H Schafer Current pharmaceutical biotechnology 13 (11), 2259-2272, 2012 | 93 | 2012 |
Suramin inhibits death receptor–induced apoptosis in vitro and fulminant apoptotic liver damage in mice ST Eichhorst, A Krueger, S Müerköster, SC Fas, A Golks, U Gruetzner, ... Nature medicine 10 (6), 602-609, 2004 | 93 | 2004 |
Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells HH Oberg, C Kellner, D Gonnermann, S Sebens, D Bauerschlag, ... Frontiers in immunology 9, 814, 2018 | 92 | 2018 |
Identification and characterization of two functional variants in the human longevity gene FOXO3 F Flachsbart, J Dose, L Gentschew, C Geismann, A Caliebe, C Knecht, ... Nature communications 8 (1), 2063, 2017 | 91 | 2017 |